The unproven stem cell clinic firm US Stem Cell Inc. is in a world of hurt. If a federal judge says you can no longer sell your key commercial offering, how do you survive as a company? US Stem probably has been thinking about that possibility for months. Still, it’s not yet clear where the […]
Can clinic biz US Stem reboot after losing suit? Its email to customers & more Read More »
What are your weekend reads? Many of us scientists read up on specific articles over the weekend that caught our eye during the last week or two. Here are some of my weekend reads plus some other stuff that just generally looked really interesting or unusual. The list includes both primary papers and news articles
Stem cell & other science weekend reads: arteries, diabetes, iffy metaphors, & more Read More »
Something very strange just happened at the journal Nature related to what’s called Muse cells. Kudos to them for dealing with it quickly though. They published an unreviewed research “article” on controversial (perhaps non-existent) stem cells called “Muse cells” that was actually a paid advertisement. After I communicated with the Nature team eventually they ended up
Nature yanks article that was actually advertisement on controversial stem cells Read More »
Does a new lawsuit including Cell Surgical Network and its leadership as defendants pose a broad test to this entire chain of stem cell clinics, which may be the largest such affiliated clinic group in the U.S. and potentially even in the world? Will lawsuits substantially impact stem cell clinics? Lawsuits against unproven, for-profit stem cell
New lawsuit includes big stem cell clinic chain, Cell Surgical Network Read More »
What is stem cell media? When us scientists hear the phrase “stem cell media” we usually think about the liquid food that we feed our stem cells in the lab, which resembles a kind of nutrient-rich Kool-aid, but another kind of stem cell media consists of the news coverage of stem cells. This other kind
Grading 3 stem cell media reports on clinical science: vision, MS, & paralysis Read More »
Did you hear the one about the deep state FDA, big pharma stem cell conspiracy theory? This is the phony idea that the FDA, big pharma, and, heck, sometimes even certain academics (who could that be?) are plotting together as some kind of biomedical secret society or “deep state” to block promising stem cell therapies
Predatory clinics push stem cell secret society, deep state conspiracy theory Read More »
When you think of Florida, what else crosses your mind first? Orange juice? Heat and humidity? Beaches? Disney? I don’t know if this says more about me or the state, but these days I think of stem cells. Florida and California are the two biggest hotbeds of the for-profit stem cell clinic world, each with
Sentinel Takes Investigational Deep Dive into Florida Stem Cell Clinic Soup Read More »
A list of stuff for your weekend reading enjoyment ranging from research pubs to news to commentary. Electrical Stimulation Steers Neural Stem Cells. Way to go UC Davis team; see image at right. Stem cell therapies: medical experts call for strict international rules. A team calls for global efforts. Stem cells in court: historical trends in US
TGIF: Stem cell and science weekend reads Read More »
Today’s post is the last of a three-part series on the Burt stem cell trials at Northwestern. This piece is focused on funding and the future of the trial, and also includes perspectives from patients. You can read Part 1 here and Part 2 here, which focused on issues related to potential encouragement of patient fundraising that unintentionally releases
Burt Northwestern Stem Cell MS Trial Part 3: Funding, Patient Perspectives, & the Future Read More »
Can science now cure MS in some patients with stem cells or is that near on the horizon? What about stem cells for other serious autoimmune disorders? What are the risks to patients in terms of health, money, and hope? What if patients must find $100,000 or $200,000 just to get into a clinical trial for
Burt Northwestern Stem Cell MS Trial Part 2: Marketing ‘Cure’-Like Outcomes? Read More »